A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1

Trial Profile

A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Brodalumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms AMAGINE-1
  • Sponsors Amgen
  • Most Recent Events

    • 12 Oct 2017 Results published in an Ortho Dermatologics Media Release
    • 03 Oct 2017 Results (n=4464) of exploratory analysis assessing psychiatric adverse events occurrence across late stage brodalumab patients using patient data from NCT00975637, NCT01101100, NCT01708590, NCT01708603 and NCT01708629 trials and their open label extensions published in the Journal of the American Academy of Dermatology
    • 14 Sep 2017 Results from AMAGINE-1,AMAGINE-2 and AMAGINE-3 studies were presented at the 26th European Academy of Dermatology (EADV) annual congress 2017, as reported in a LEO Pharma media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top